Antitrust matters are rarely isolated within a single state or federal agency or jurisdiction. We represent clients facing multi-dimensional antitrust challenges on the transactional, regulatory and litigation fronts, mobilizing an unmatched combination of courtroom excellence, government experience and legal, economic and academic prowess on our clients’ behalf.
Paul, Weiss is representing Elanco Animal Health Inc. in the corporate and antitrust aspects of its $7.6 billion acquisition of the animal health business of Germany-based pharmaceutical giant Bayer AG.
U.S. and E.U. competition agencies have announced temporary changes in their merger review procedures as a result of the COVID-19 pandemic. Significantly, the U.S. antitrust agencies will not grant any requests for early termination. Competition review and approval delays are possible on a global basis. We review developments in competition enforcement in light of the pandemic.
New York legislators introduced a bill, S. 8700-A, that would expand the reach of New York’s antitrust law and may create greater liability exposure for corporations doing business in the state. The bill redefines the nature of antitrust offenses to cover a wide variety of unilateral business conduct by large or “dominant” corporations, potentially adopting standards prevalent in the European Union but not in the United States.
DOJ Resolves Criminal Product Market Allocation Charge with $100 Million Penalty and Deferred Prosecution Agreement
The Department of Justice (DOJ) announced that a Florida oncology group has agreed to pay a criminal penalty of $100 million, which is the statutory maximum amount, to resolve a charge that it conspired with a competing group to enter into a product allocation scheme involving types of cancer treatments.
Paul, Weiss is advising Cigna Corporation on the regulatory clearance of the $6.3 billion sale of its group life and disability insurance business to New York Life.
On June 30, the DOJ and Federal Trade Commission issued final vertical merger guidelines that provide executives, dealmakers and their advisors with important insight into how the federal agencies are likely to evaluate a deal with vertical elements, including whether a deal is likely to be challenged by the agencies.
On July 9, the Supreme Court granted review in AMG Capital v. Federal Trade Commission and Federal Trade Commission v. Credit Bureau Center to decide whether a federal court can award monetary relief in the form of restitution in an action brought by the FTC under Section 13(b) of the FTC Act.
Cigna announced that the Antitrust Division of the DOJ cleared Cigna’s $67 billion acquisition of pharmacy benefits manager Express Scripts Holding.